Company intelligence / Profile preview

Medneon

Cupertino* or general CA location, California, United Statesprnewswire.com ↗

Ownership: Private
Employees: ~10
Development stage: Commercial

Overview

Medneon's main product was the Predictive Risk Assessment™ tool, which integrates guidelines, real-world evidence, and personal/family history to assess genetic risk for hereditary cancers. Its iGAP Registry aimed to correlate genetic results with clinical outcomes in breast cancer prevention. The company was acquired by Invitae in mid–2021 for $34.1 million. No drug or therapeutic clinical results.

Therapeutic areas: OncologyRare DiseasesWomen's Health
Industry: Molecular Diagnostics

Partnerships

Integrated into Invitae's education and clinical support offerings post-acquisition; no major external pharma partnerships disclosed pre-acquisition.

Beyond the preview

Go deeper on Medneon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medneon.

Explore the full profile